United Therapeutics Stock Price, News & Analysis (NASDAQ:UTHR)

$134.93 -1.18 (-0.87 %)
(As of 02/20/2018 08:30 AM ET)
Previous Close$136.11
Today's Range$134.77 - $139.22
52-Week Range$112.01 - $169.89
Volume330,500 shs
Average Volume400,058 shs
Market Capitalization$5.83 billion
P/E Ratio11.90
Dividend YieldN/A
Beta1.26

About United Therapeutics (NASDAQ:UTHR)

United Therapeutics logoUnited Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:UTHR
CUSIP91307C10
Phone301-608-9292

Debt

Debt-to-Equity RatioN/A
Current Ratio2.08%
Quick Ratio1.93%

Price-To-Earnings

Trailing P/E Ratio11.8985890652557
Forward P/E Ratio10.41
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.60 billion
Price / Sales3.65
Cash Flow$17.57 per share
Price / Cash7.68
Book Value$43.65 per share
Price / Book3.09

Profitability

Trailing EPS$11.34
Net Income$713.70 million
Net Margins30.50%
Return on Equity26.24%
Return on Assets19.37%

Miscellaneous

Employees750
Outstanding Shares43,210,000

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics' stock buyback program work?

United Therapeutics declared that its Board of Directors has initiated a share buyback plan on Sunday, June 4th 2017, which authorizes the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 4.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its shares are undervalued.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, October, 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $4.01 by $2.26. The biotechnology company earned $445.50 million during the quarter, compared to the consensus estimate of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. United Therapeutics's revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $4.23 earnings per share. View United Therapeutics' Earnings History.

When will United Therapeutics make its next earnings announcement?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for United Therapeutics.

Where is United Therapeutics' stock going? Where will United Therapeutics' stock price be in 2018?

9 brokers have issued twelve-month price targets for United Therapeutics' stock. Their predictions range from $95.00 to $232.00. On average, they expect United Therapeutics' share price to reach $141.89 in the next year. View Analyst Ratings for United Therapeutics.

What are Wall Street analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:

  • 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company, at present, has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. However, increased competitive pressure from Uptravi on its PAH drugs, mainly Orenitram, is a concern. We believe the company needs to use cash suitably to deal with generic competition for Remodulin that could materialize post Jun 2018. However, United Therapeutics’ shares have outperformed the industry in the past six months. Estimates have gone up ahead of the Q4 earnings release. The company has a mixed record of earnings surprises in the recent quarters. " (1/15/2018)
  • 2. Cowen Inc analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
  • 3. Credit Suisse Group AG analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
  • 4. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
  • 5. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)

Who are some of United Therapeutics' key competitors?

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:

  • Martine A. Rothblatt Ph.D. J.D., Chairman of the Board, Chief Executive Officer (Age 62)
  • Michael Benkowitz, President, Chief Operating Officer (Age 45)
  • Christopher Patusky J.D., Lead Independent Vice Chairman of the Board (Age 53)
  • James C. Edgemond, Chief Financial Officer, Treasurer (Age 49)
  • Paul A. Mahon J.D., Executive Vice President, General Counsel, Corporate Secretary (Age 53)
  • Raymond A. Dwek, Non-Independent Director (Age 75)
  • Christopher Causey, Independent Director (Age 54)
  • Richard A. Giltner, Independent Director (Age 53)
  • Katherine J. Klein Ph.D., Independent Director (Age 60)
  • Raymond C. Kurzweil J.D., Independent Director (Age 69)

Who owns United Therapeutics stock?

United Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.04%), Palo Alto Investors LLC (3.72%), Renaissance Technologies LLC (3.38%), Acadian Asset Management LLC (2.59%), Old Mutual Global Investors UK Ltd. (2.17%) and Schroder Investment Management Group (1.99%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Who sold United Therapeutics stock? Who is selling United Therapeutics stock?

United Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Palo Alto Investors LLC, Gotham Asset Management LLC, Millennium Management LLC, Geode Capital Management LLC, Allianz Asset Management GmbH, Old Mutual Global Investors UK Ltd. and BlackRock Inc.. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Causey, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Who bought United Therapeutics stock? Who is buying United Therapeutics stock?

United Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Renaissance Technologies LLC, LSV Asset Management, Capital Fund Management S.A., First Trust Advisors LP, APG Asset Management N.V., Armistice Capital LLC and Cornerstone Capital Management Holdings LLC.. View Insider Buying and Selling for United Therapeutics.

How do I buy United Therapeutics stock?

Shares of United Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of United Therapeutics stock can currently be purchased for approximately $134.93.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $5.83 billion and generates $1.60 billion in revenue each year. The biotechnology company earns $713.70 million in net income (profit) each year or $11.34 on an earnings per share basis. United Therapeutics employs 750 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics (UTHR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  328 (Vote Outperform)
Underperform Votes:  430 (Vote Underperform)
Total Votes:  758
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

United Therapeutics (NASDAQ:UTHR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.001.911.91
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $141.89$141.89$135.50$134.70
Price Target Upside: 1.40% upside1.40% upside13.77% upside3.12% upside

United Therapeutics (NASDAQ:UTHR) Consensus Price Target History

Price Target History for United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ:UTHR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2018Credit Suisse GroupReiterated RatingUnderperform -> Underperform$118.00LowView Rating Details
1/5/2018OppenheimerBoost Price TargetOutperform$180.00LowView Rating Details
12/27/2017WedbushReiterated RatingOutperform -> Outperform$213.00 -> $232.00MediumView Rating Details
10/27/2017CowenReiterated RatingHold$129.00N/AView Rating Details
10/26/2017HC WainwrightReiterated RatingHold$95.00N/AView Rating Details
7/14/2017Jefferies GroupReiterated RatingSell$105.00LowView Rating Details
4/11/2017JPMorgan Chase & Co.Set Price TargetHold$125.00LowView Rating Details
2/23/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$145.00N/AView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$127.00 -> $148.00N/AView Rating Details
1/19/2017Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
11/29/2016BarclaysDowngradeEqual Weight -> Underweight$115.00 -> $100.00N/AView Rating Details
8/23/2016ArgusReiterated RatingHoldN/AView Rating Details
4/11/2016Royal Bank of CanadaReiterated RatingSector Perform$150.00 -> $122.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

United Therapeutics (NASDAQ:UTHR) Earnings History and Estimates Chart

Earnings by Quarter for United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ UTHR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$3.59N/AView Earnings Details
10/25/2017Q3 2017$4.01$6.27$426.43 million$445.50 millionViewN/AView Earnings Details
7/27/2017Q2 2017$3.61($1.25)$391.53 million$444.60 millionViewN/AView Earnings Details
4/26/2017Q1 2017$3.13$3.89$399.59 million$370.50 millionViewN/AView Earnings Details
2/22/2017Q416$3.61$4.12$415.51 million$409.00 millionViewListenView Earnings Details
10/27/2016Q316$3.38$4.36$400.58 million$408.20 millionViewListenView Earnings Details
7/28/2016Q216$3.22$4.55$395.15 million$412.60 millionViewListenView Earnings Details
4/28/2016Q116$3.21$3.02$395.02 million$369.00 millionViewListenView Earnings Details
2/25/2016Q415$2.70$3.68$388.29 million$404.90 millionViewListenView Earnings Details
10/27/2015Q315$2.35$3.55$363.51 million$386.20 millionViewListenView Earnings Details
7/28/2015Q215$2.31$2.55$360.41 million$347.20 millionViewListenView Earnings Details
4/28/2015Q115$2.14$2.55$353.50 million$327.60 millionViewN/AView Earnings Details
2/24/2015Q414$2.03$3.21$336.22 million$346.40 millionViewN/AView Earnings Details
10/28/2014Q314$1.97$3.91$335.10 million$330.00 millionViewN/AView Earnings Details
7/29/2014Q214$1.75$2.57$308.04 million$322.80 millionViewN/AView Earnings Details
4/29/2014Q114$1.65$1.77$300.14 million$289.40 millionViewN/AView Earnings Details
2/25/2014Q413$1.51$2.88$295.43 million$289.02 millionViewN/AView Earnings Details
10/29/2013Q313$1.59$2.98$279.02 million$302.20 millionViewN/AView Earnings Details
7/25/2013Q2 2013$1.47$1.52$250.17 million$280.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013$1.47$1.19$241.14 million$245.14 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.25$1.65$233.41 million$243.82 millionViewN/AView Earnings Details
11/1/2012Q312$1.26$2.82$227.63 million$242.50 millionViewN/AView Earnings Details
7/26/2012$1.23$1.34ViewN/AView Earnings Details
4/26/2012$1.00$1.32ViewN/AView Earnings Details
2/14/2012$0.85$0.77ViewN/AView Earnings Details
10/27/2011$0.88$1.32ViewN/AView Earnings Details
7/28/2011$0.49$1.27ViewN/AView Earnings Details
4/28/2011$0.64$1.29ViewN/AView Earnings Details
2/15/2011$0.62$0.15ViewN/AView Earnings Details
10/28/2010Q3 2010$0.54$0.66ViewN/AView Earnings Details
7/28/2010Q2 2010$0.45$0.62ViewN/AView Earnings Details
4/29/2010Q1 2010$0.30$0.32ViewN/AView Earnings Details
2/16/2010Q4 2009$0.28$0.16ViewN/AView Earnings Details
10/29/2009Q3 2009$0.34$0.21ViewN/AView Earnings Details
7/31/2009Q2 2009$0.28($0.05)ViewN/AView Earnings Details
5/1/2009Q1 2009$0.31$0.24ViewN/AView Earnings Details
2/17/2009Q4 2008$0.26$0.43ViewN/AView Earnings Details
10/30/2008Q3 2008$0.30$0.25ViewN/AView Earnings Details
7/31/2008Q2 2008$0.30$0.29ViewN/AView Earnings Details
5/1/2008Q1 2008$0.27$0.24ViewN/AView Earnings Details
2/19/2008Q4 2007$0.25$0.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

United Therapeutics (NASDAQ:UTHR) Earnings Estimates

2018 EPS Consensus Estimate: $11.92
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$3.20$3.61$3.41
Q2 20182$2.82$3.47$3.15
Q3 20182$2.44$3.07$2.76
Q4 20182$2.28$2.95$2.62
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for United Therapeutics (NASDAQ:UTHR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

United Therapeutics (NASDAQ UTHR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.80%
Insider Trades by Quarter for United Therapeutics (NASDAQ:UTHR)
Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

United Therapeutics (NASDAQ UTHR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2017Martine A RothblattCEOSell1$136.16$136.16141View SEC Filing  
12/7/2017Christopher CauseyDirectorSell580$134.72$78,137.601,555View SEC Filing  
11/30/2017Martine A RothblattCEOSell1,241$128.95$160,026.95View SEC Filing  
11/24/2017Martine A RothblattCEOSell1,253$124.07$155,459.71View SEC Filing  
11/16/2017Martine A RothblattCEOSell7,061$121.12$855,228.32View SEC Filing  
11/9/2017Martine A RothblattCEOSell1,260$121.46$153,039.601,400View SEC Filing  
11/6/2017Christopher CauseyDirectorSell580$122.00$70,760.002,135View SEC Filing  
11/2/2017Martine A RothblattCEOSell1,269$118.04$149,792.761,409View SEC Filing  
10/26/2017Martine A RothblattCEOSell1,263$120.38$152,039.941,403View SEC Filing  
10/19/2017Martine A RothblattCEOSell1,265$119.38$151,015.701,405View SEC Filing  
10/12/2017Martine A RothblattCEOSell1,263$120.20$151,812.60View SEC Filing  
10/5/2017Christopher CauseyDirectorSell580$122.00$70,760.00View SEC Filing  
10/5/2017Martine A RothblattCEOSell1,256$122.98$154,462.88View SEC Filing  
9/28/2017Martine A RothblattCEOSell1,265$119.70$151,420.502,334View SEC Filing  
9/21/2017Martine A RothblattCEOSell1,274$116.07$147,873.182,343View SEC Filing  
9/14/2017Martine A RothblattCEOSell1,258$122.08$153,576.642,327View SEC Filing  
9/7/2017Christopher CauseyDirectorSell580$134.48$77,998.403,295View SEC Filing  
9/7/2017Martine A RothblattCEOSell1,232$133.32$164,250.242,301View SEC Filing  
8/31/2017Martine A RothblattCEOSell1,235$130.49$161,155.152,304View SEC Filing  
8/24/2017Martine A RothblattCEOSell1,238$130.65$161,744.702,307View SEC Filing  
8/17/2017Martine A RothblattCEOSell1,235$131.95$162,958.252,304View SEC Filing  
8/10/2017Martine A RothblattCEOSell2,176$127.11$276,591.363,245View SEC Filing  
8/3/2017Martine A RothblattCEOSell1,248$126.41$157,759.682,317View SEC Filing  
7/27/2017Martine A RothblattCEOSell1,247$126.40$157,620.802,316View SEC Filing  
7/20/2017Martine A RothblattCEOSell1,236$131.62$162,682.321,376View SEC Filing  
7/13/2017Martine A RothblattCEOSell1,238$130.44$161,484.721,378View SEC Filing  
7/6/2017Christopher CauseyDirectorSell590$132.61$78,239.903,875View SEC Filing  
7/6/2017Martine A RothblattCEOSell1,234$132.29$163,245.861,374View SEC Filing  
7/5/2017Richard GiltnerDirectorSell3,490$131.12$457,608.80View SEC Filing  
6/29/2017Martine A RothblattCEOSell1,237$130.92$161,948.041,377View SEC Filing  
6/23/2017Raymond DwekDirectorSell3,490$131.71$459,667.90View SEC Filing  
6/22/2017Martine A RothblattCEOSell1,234$132.32$163,282.881,374View SEC Filing  
6/15/2017Martine A RothblattCEOSell1,238$130.20$161,187.601,378View SEC Filing  
6/8/2017Martine A RothblattCEOSell1,240$129.60$160,704.001,380View SEC Filing  
6/1/2017Martine A RothblattCEOSell1,251$125.02$156,400.021,391View SEC Filing  
5/25/2017Martine A RothblattCEOSell1,265$119.40$151,041.001,405View SEC Filing  
5/18/2017Martine A RothblattCEOSell1,261$120.72$152,227.921,401View SEC Filing  
5/11/2017Martine A RothblattCEOSell1,259$122.00$153,598.001,399View SEC Filing  
5/4/2017Martine A RothblattCEOSell1,258$122.24$153,777.921,398View SEC Filing  
4/27/2017Martine A RothblattCEOSell1,262$120.78$152,424.361,402View SEC Filing  
4/20/2017Martine A RothblattCEOSell1,260$121.14$152,636.401,400View SEC Filing  
4/13/2017Martine A RothblattCEOSell1,258$122.12$153,626.961,398View SEC Filing  
4/6/2017Martine A RothblattCEOSell1,257$122.39$153,844.231,397View SEC Filing  
3/30/2017Martine A RothblattCEOSell1,230$134.56$165,508.801,370View SEC Filing  
3/23/2017Martine A RothblattCEOSell1,219$139.33$169,843.271,359View SEC Filing  
3/22/2017Tommy G ThompsonDirectorSell2,000$139.37$278,740.002,000View SEC Filing  
3/16/2017Martine A RothblattCEOSell1,218$140.16$170,714.881,358View SEC Filing  
3/9/2017Martine A RothblattCEOSell1,206$146.72$176,944.321,346View SEC Filing  
3/2/2017Martine A RothblattCEOSell1,203$148.49$178,633.471,343View SEC Filing  
2/23/2017Martine A RothblattCEOSell1,208$145.16$175,353.281,348View SEC Filing  
2/16/2017Martine A RothblattCEOSell1,173$167.92$196,970.161,313View SEC Filing  
1/12/2017Christopher PatuskyDirectorSell5,000$141.99$709,950.005,000View SEC Filing  
1/12/2017Martine A RothblattCEOSell1,214$142.37$172,837.181,354View SEC Filing  
1/5/2017Martine A RothblattCEOSell1,208$145.73$176,041.841,348View SEC Filing  
12/29/2016Martine A RothblattCEOSell1,211$143.63$173,935.931,351View SEC Filing  
12/22/2016Martine A RothblattCEOSell1,218$140.23$170,800.141,358View SEC Filing  
12/15/2016Martine A RothblattCEOSell1,212$143.11$173,449.321,352View SEC Filing  
12/8/2016Martine A RothblattCEOSell1,236$131.78$162,880.081,376View SEC Filing  
12/6/2016Richard GiltnerDirectorSell5,000$133.37$666,850.005,000View SEC Filing  
12/1/2016Martine A RothblattCEOSell1,246$126.86$158,067.561,386View SEC Filing  
11/25/2016Martine A RothblattCEOSell1,233$132.81$163,754.731,373View SEC Filing  
11/17/2016Martine A RothblattCEOSell1,232$132.94$163,782.081,372View SEC Filing  
11/10/2016Christopher PatuskyDirectorSell5,000$131.42$657,100.005,000View SEC Filing  
11/10/2016Martine A RothblattCEOSell1,240$129.82$160,976.801,380View SEC Filing  
11/3/2016Martine A RothblattCEOSell1,272$116.94$148,747.681,412View SEC Filing  
10/27/2016Martine A RothblattCEOSell1,272$117.06$148,900.321,412View SEC Filing  
10/20/2016Martine A RothblattCEOSell1,282$113.30$145,250.601,422View SEC Filing  
10/13/2016Martine A RothblattCEOSell1,269$117.99$149,729.311,409View SEC Filing  
10/6/2016Martine A RothblattCEOSell1,260$121.17$152,674.201,400View SEC Filing  
9/29/2016Martine A RothblattCEOSell1,272$116.94$148,747.681,412View SEC Filing  
9/26/2016Tommy G ThompsonDirectorSell1,291$125.57$162,110.871,291View SEC Filing  
9/22/2016Martine A RothblattCEOSell1,249$125.87$157,211.631,389View SEC Filing  
9/15/2016Martine A RothblattCEOSell1,258$122.34$153,903.721,398View SEC Filing  
9/8/2016Martine A RothblattCEOSell1,254$123.44$154,793.761,394View SEC Filing  
9/1/2016Christopher PatuskyDirectorSell5,000$122.73$613,650.005,000View SEC Filing  
9/1/2016Martine A RothblattCEOSell1,257$122.81$154,372.171,397View SEC Filing  
8/25/2016Martine A RothblattCEOSell1,250$125.29$156,612.501,390View SEC Filing  
8/18/2016Martine A RothblattCEOSell1,249$125.88$157,224.121,389View SEC Filing  
8/11/2016Martine A RothblattCEOSell1,253$124.09$155,484.771,393View SEC Filing  
8/4/2016Martine A RothblattCEOSell1,249$125.78$157,099.221,389View SEC Filing  
7/28/2016Martine A RothblattCEOSell1,271$117.05$148,770.551,411View SEC Filing  
7/21/2016Martine A RothblattCEOSell1,284$112.77$144,796.681,424View SEC Filing  
7/14/2016Martine A RothblattCEOSell1,292$110.05$142,184.601,432View SEC Filing  
7/7/2016Martine A RothblattCEOSell1,293$109.87$142,061.911,433View SEC Filing  
6/30/2016Martine A RothblattCEOSell1,308$105.10$137,470.801,548View SEC Filing  
6/23/2016Martine A RothblattCEOSell1,312$104.07$136,539.841,552View SEC Filing  
6/16/2016Martine A RothblattCEOSell1,308$105.18$137,575.441,548View SEC Filing  
6/9/2016Martine A RothblattCEOSell1,277$114.99$146,842.231,517View SEC Filing  
6/8/2016Tommy G ThompsonDirectorSell2,000$115.62$231,240.002,000View SEC Filing  
6/2/2016Martine A RothblattCEOSell1,261$120.79$152,316.191,501View SEC Filing  
6/2/2016Raymond DwekDirectorSell3,000$118.82$356,460.003,000View SEC Filing  
5/26/2016Martine A RothblattCEOSell5,547$117.57$652,160.795,787View SEC Filing  
5/19/2016Martine A RothblattCEOSell5,546$110.75$614,219.505,786View SEC Filing  
5/12/2016Martine A RothblattCEOSell5,547$109.02$604,733.945,787View SEC Filing  
5/12/2016Raymond DwekDirectorSell3,000$110.00$330,000.003,000View SEC Filing  
5/5/2016Martine A RothblattCEOSell5,546$107.79$597,803.345,786View SEC Filing  
4/28/2016Martine A RothblattCEOSell5,547$106.81$592,475.075,787View SEC Filing  
4/21/2016Martine A RothblattCEOSell5,546$115.74$641,894.045,786View SEC Filing  
4/14/2016Martine A RothblattCEOSell5,547$114.32$634,133.045,787View SEC Filing  
4/7/2016Martine A RothblattCEOSell5,546$113.31$628,417.265,786View SEC Filing  
3/24/2016Martine A RothblattCEOSell5,546$110.80$614,496.805,786View SEC Filing  
3/17/2016Martine A RothblattCEOSell5,547$118.22$655,766.345,787View SEC Filing  
3/10/2016Martine A RothblattCEOSell5,546$123.41$684,431.865,786View SEC Filing  
3/3/2016Martine A RothblattCEOSell5,547$126.78$703,248.665,787View SEC Filing  
2/25/2016Martine A RothblattCEOSell5,546$122.45$679,107.705,786View SEC Filing  
2/18/2016Martine A RothblattCEOSell5,547$128.26$711,458.225,787View SEC Filing  
2/11/2016Martine A. RothblattCEOSell5,546$120.47$668,126.62240View SEC Filing  
2/4/2016Martine A. RothblattCEOSell5,547$122.13$677,455.11240View SEC Filing  
2/4/2016Raymond DwekDirectorSell3,000$122.66$367,980.00View SEC Filing  
1/28/2016Martine A. RothblattCEOSell5,546$124.00$687,704.00240View SEC Filing  
1/21/2016Martine A. RothblattCEOSell5,547$127.00$704,469.00240View SEC Filing  
1/14/2016Martine A. RothblattCEOSell5,546$135.94$753,923.24240View SEC Filing  
1/7/2016Martine A. RothblattCEOSell5,547$145.84$808,974.48240View SEC Filing  
1/7/2016Raymond DwekDirectorSell3,000$143.75$431,250.00View SEC Filing  
12/24/2015Martine A. RothblattCEOSell5,546$159.58$885,030.68240View SEC Filing  
12/17/2015Martine A. RothblattCEOSell5,546$158.49$878,985.54240View SEC Filing  
12/10/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54240View SEC Filing  
12/3/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54240View SEC Filing  
12/3/2015Raymond DwekDirectorSell3,000$157.22$471,660.00View SEC Filing  
11/27/2015Martine A. RothblattCEOSell5,561$153.81$855,337.41240View SEC Filing  
11/19/2015Martine A. RothblattCEOSell9,661$148.56$1,435,238.16240View SEC Filing  
11/12/2015Martine A. RothblattCEOSell4,115$147.72$607,867.80240View SEC Filing  
11/5/2015Martine A. RothblattCEOSell4,115$149.16$613,793.40240View SEC Filing  
11/5/2015Raymond DwekDirectorSell3,000$149.63$448,890.00View SEC Filing  
11/3/2015Richard GiltnerDirectorSell7,500$153.22$1,149,150.00View SEC Filing  
10/29/2015Martine A. RothblattCEOSell9,662$141.89$1,370,941.18240View SEC Filing  
10/28/2015Martine A. RothblattCEOSell2,211$136.58$301,978.38240View SEC Filing  
10/26/2015Martine A. RothblattCEOSell2,592$127.13$329,520.96240View SEC Filing  
10/22/2015Martine A. RothblattCEOSell9,662$122.40$1,182,628.80240View SEC Filing  
10/21/2015Martine A. RothblattCEOSell2,211$123.63$273,345.93240View SEC Filing  
10/19/2015Martine A. RothblattCEOSell2,592$126.71$328,432.32240View SEC Filing  
10/15/2015Martine A. RothblattCEOSell9,662$126.22$1,219,537.64240View SEC Filing  
10/14/2015Martine A. RothblattCEOSell2,211$123.53$273,124.83240View SEC Filing  
10/12/2015Martine A. RothblattCEOSell2,592$123.51$320,137.92240View SEC Filing  
10/8/2015Martine A. RothblattCEOSell9,662$122.48$1,183,401.76240View SEC Filing  
10/7/2015Martine A. RothblattCEOSell2,211$120.88$267,265.68240View SEC Filing  
10/5/2015Martine A. RothblattCEOSell2,592$126.88$328,872.96240View SEC Filing  
10/1/2015Martine A. RothblattCEOSell6,326$131.11$829,401.86240View SEC Filing  
10/1/2015Paul A. MahonEVPSell6,000$129.38$776,280.0035,054View SEC Filing  
10/1/2015Raymond DwekDirectorSell3,000$131.32$393,960.00View SEC Filing  
9/29/2015Martine A. RothblattCEOSell2,592$134.25$347,976.00240View SEC Filing  
9/29/2015Tommy G. ThompsonDirectorSell5,000$139.19$695,950.00View SEC Filing  
9/24/2015Martine A. RothblattCEOSell9,662$139.26$1,345,530.12240View SEC Filing  
9/23/2015Martine A. RothblattCEOSell2,211$142.05$314,072.55240View SEC Filing  
9/21/2015Martine A. RothblattCEOSell2,592$150.81$390,899.52240View SEC Filing  
9/17/2015Martine A. RothblattCEOSell9,662$152.02$1,468,817.24240View SEC Filing  
9/16/2015Martine A. RothblattCEOSell2,211$151.93$335,917.23240View SEC Filing  
9/14/2015Martine A. RothblattCEOSell2,592$153.08$396,783.36240View SEC Filing  
9/10/2015Martine A. RothblattCEOSell4,115$152.95$629,389.25240View SEC Filing  
9/9/2015Martine A. RothblattCEOSell2,211$152.77$337,774.47240View SEC Filing  
9/8/2015Martine A. RothblattCEOSell2,592$152.80$396,057.60240View SEC Filing  
9/3/2015Martine A. RothblattCEOSell9,662$153.67$1,484,759.54240View SEC Filing  
9/3/2015Raymond DwekDirectorSell3,000$155.54$466,620.00View SEC Filing  
9/2/2015Martine A. RothblattCEOSell2,211$151.12$334,126.32240View SEC Filing  
8/31/2015Martine A. RothblattCEOSell2,592$153.50$397,872.00240View SEC Filing  
8/27/2015Martine A. RothblattCEOSell9,662$160.37$1,549,494.94240View SEC Filing  
8/26/2015Martine A. RothblattCEOSell2,211$155.47$343,744.17240View SEC Filing  
8/24/2015Martine A. RothblattCEOSell2,592$155.36$402,693.12240View SEC Filing  
8/20/2015Martine A. RothblattCEOSell9,662$166.58$1,609,495.96240View SEC Filing  
8/19/2015Martine A. RothblattCEOSell2,211$167.13$369,524.43240View SEC Filing  
8/17/2015Martine A RothblattCEOSell2,592$166.61$431,853.12View SEC Filing  
8/13/2015Martine A RothblattCEOSell9,662$165.05$1,594,713.10View SEC Filing  
7/27/2015Martine A RothblattCEOSell2,592$166.38$431,256.96View SEC Filing  
7/23/2015Martine A RothblattCEOSell4,115$176.38$725,803.70View SEC Filing  
7/22/2015Martine A RothblattCEOSell2,211$174.55$385,930.05View SEC Filing  
7/20/2015Martine A RothblattCEOSell2,592$177.92$461,168.64View SEC Filing  
7/16/2015Martine A RothblattCEOSell9,662$175.51$1,695,777.62View SEC Filing  
7/15/2015Martine A RothblattCEOSell2,211$176.77$390,838.47View SEC Filing  
7/13/2015Martine A RothblattCEOSell2,592$172.42$446,912.64View SEC Filing  
7/9/2015Martine A RothblattCEOSell9,662$168.04$1,623,602.48View SEC Filing  
7/8/2015Martine A RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
7/6/2015Martine A RothblattCEOSell2,592$170.66$442,350.72View SEC Filing  
7/2/2015Martine A RothblattCEOSell6,326$170.69$1,079,784.94View SEC Filing  
7/2/2015Raymond DwekDirectorSell3,000$171.59$514,770.00View SEC Filing  
6/29/2015Martine A RothblattCEOSell2,592$172.86$448,053.12View SEC Filing  
6/25/2015Martine A RothblattCEOSell9,662$176.91$1,709,304.42View SEC Filing  
6/24/2015Martine A RothblattCEOSell2,211$179.68$397,272.48View SEC Filing  
6/22/2015Martine A RothblattCEOSell2,592$188.64$488,954.88View SEC Filing  
6/18/2015Louis W SullivanDirectorSell15,000$185.60$2,784,000.00View SEC Filing  
6/18/2015Martine A RothblattCEOSell9,662$185.72$1,794,426.64View SEC Filing  
6/17/2015Martine A RothblattCEOSell2,211$185.25$409,587.75View SEC Filing  
6/15/2015Martine A RothblattCEOSell2,592$185.15$479,908.80View SEC Filing  
6/11/2015Martine A RothblattCEOSell9,662$183.76$1,775,489.12View SEC Filing  
6/10/2015Martine A RothblattCEOSell2,211$180.87$399,903.57View SEC Filing  
6/8/2015Martine A RothblattCEOSell2,592$181.34$470,033.28View SEC Filing  
6/4/2015Martine A RothblattCEOSell9,662$181.94$1,757,904.28View SEC Filing  
6/4/2015Raymond DwekDirectorSell3,000$181.36$544,080.00View SEC Filing  
6/3/2015Martine A RothblattCEOSell2,211$184.49$407,907.39View SEC Filing  
6/1/2015Martine A RothblattCEOSell2,592$182.66$473,454.72View SEC Filing  
5/28/2015Martine A RothblattCEOSell9,662$180.88$1,747,662.56View SEC Filing  
5/27/2015Martine A RothblattCEOSell2,211$184.39$407,686.29View SEC Filing  
5/26/2015Martine A RothblattCEOSell2,592$182.64$473,402.88View SEC Filing  
5/21/2015Martine A RothblattCEOSell9,662$182.44$1,762,735.28View SEC Filing  
5/21/2015Tommy G ThompsonDirectorSell1,500$182.04$273,060.00View SEC Filing  
5/20/2015Martine A RothblattCEOSell2,211$182.80$404,170.80View SEC Filing  
5/18/2015Martine A RothblattCEOSell2,592$177.79$460,831.68View SEC Filing  
5/14/2015Martine A RothblattCEOSell9,662$174.07$1,681,864.34View SEC Filing  
5/13/2015Martine A RothblattCEOSell2,211$175.41$387,831.51View SEC Filing  
5/11/2015Martine A RothblattCEOSell2,592$179.55$465,393.60View SEC Filing  
5/7/2015Christopher CauseyDirectorSell1,500$167.94$251,910.00View SEC Filing  
5/7/2015Martine A RothblattCEOSell9,662$169.86$1,641,187.32View SEC Filing  
5/6/2015Martine A RothblattCEOSell2,211$169.22$374,145.42View SEC Filing  
5/4/2015Martine A RothblattCEOSell2,592$169.81$440,147.52View SEC Filing  
5/1/2015Raymond DwekDirectorSell3,000$159.58$478,740.00View SEC Filing  
4/30/2015Martine A RothblattCEOSell9,662$162.36$1,568,722.32View SEC Filing  
4/29/2015Martine A RothblattCEOSell2,211$164.29$363,245.19View SEC Filing  
4/28/2015Roger JeffsCEOSell5,000$163.31$816,550.00View SEC Filing  
4/27/2015Martine A RothblattCEOSell2,592$177.62$460,391.04View SEC Filing  
4/23/2015Martine A RothblattCEOSell9,662$187.35$1,810,175.70View SEC Filing  
4/22/2015Martine A RothblattCEOSell2,211$187.49$414,540.39View SEC Filing  
4/21/2015Roger JeffsCEOSell10,000$187.86$1,878,600.00View SEC Filing  
4/20/2015Martine A RothblattCEOSell2,592$184.86$479,157.12View SEC Filing  
4/16/2015Martine A RothblattCEOSell11,873$187.01$2,220,369.73View SEC Filing  
4/16/2015Paul A MahonEVPSell6,000$187.91$1,127,460.00View SEC Filing  
4/14/2015David ZaccardelliCOOSell3,250$185.82$603,915.00View SEC Filing  
4/14/2015Roger JeffsCEOSell10,000$185.82$1,858,200.00View SEC Filing  
4/13/2015Martine A RothblattCEOSell2,592$187.86$486,933.12View SEC Filing  
4/9/2015David ZaccardelliCOOSell4,000$184.84$739,360.00View SEC Filing  
4/9/2015Martine A RothblattCEOSell9,662$183.09$1,769,015.58View SEC Filing  
4/8/2015Martine A RothblattCEOSell2,211$181.91$402,203.01View SEC Filing  
4/7/2015David ZaccardelliCOOSell4,000$179.34$717,360.00View SEC Filing  
4/7/2015Roger JeffsCEOSell10,000$179.34$1,793,400.00View SEC Filing  
4/6/2015Martine A RothblattCEOSell2,592$176.20$456,710.40View SEC Filing  
4/2/2015David ZaccardelliCOOSell4,000$174.73$698,920.00View SEC Filing  
4/2/2015Martine A RothblattCEOSell11,873$173.43$2,059,134.39View SEC Filing  
4/2/2015Paul A MahonEVPSell6,000$174.73$1,048,380.00View SEC Filing  
4/2/2015Raymond DwekDirectorSell3,000$175.49$526,470.00View SEC Filing  
3/30/2015Martine A RothblattCEOSell2,592$177.22$459,354.24View SEC Filing  
3/26/2015David ZaccardelliCOOSell4,000$167.52$670,080.00View SEC Filing  
3/26/2015Martine A RothblattCEOSell9,662$167.03$1,613,843.86View SEC Filing  
3/25/2015Martine A RothblattCEOSell2,211$173.67$383,984.37View SEC Filing  
3/24/2015David ZaccardelliCOOSell4,500$179.51$807,795.00View SEC Filing  
3/23/2015Martine A RothblattCEOSell2,592$177.76$460,753.92View SEC Filing  
3/19/2015Paul A MahonEVPSell6,000$175.82$1,054,920.00View SEC Filing  
3/18/2015Martine A RothblattCEOSell2,211$174.64$386,129.04View SEC Filing  
3/17/2015David ZaccardelliCOOSell4,000$177.34$709,360.00View SEC Filing  
3/16/2015Martine A RothblattCEOSell2,592$170.97$443,154.24View SEC Filing  
3/12/2015Martine A RothblattCEOSell11,873$162.94$1,934,586.62View SEC Filing  
3/10/2015Roger JeffsCEOSell18,750$143.68$2,694,000.00View SEC Filing  
3/9/2015Martine A RothblattCEOSell2,592$160.51$416,041.92View SEC Filing  
3/5/2015Martine A RothblattCEOSell9,662$159.75$1,543,504.50View SEC Filing  
3/5/2015Raymond DwekDirectorSell3,000$157.59$472,770.00View SEC Filing  
3/4/2015Martine A RothblattCEOSell2,211$157.63$348,519.93View SEC Filing  
3/3/2015Roger JeffsCEOSell10,000$157.74$1,577,400.00View SEC Filing  
3/2/2015Martine A RothblattCEOSell2,592$155.32$402,589.44View SEC Filing  
2/27/2015Ray KurzweilDirectorSell15,000$155.05$2,325,750.00View SEC Filing  
2/26/2015Martine A RothblattCEOSell9,662$155.23$1,499,832.26View SEC Filing  
2/25/2015Martine A RothblattCEOSell2,211$159.35$352,322.85View SEC Filing  
2/24/2015David ZaccardelliCOOSell1,458$155.16$226,223.28View SEC Filing  
2/24/2015Roger JeffsCEOSell10,000$155.16$1,551,600.00View SEC Filing  
2/23/2015Martine A RothblattCEOSell2,592$156.08$404,559.36View SEC Filing  
2/19/2015John Maxim FerrariCFOSell10,000$155.72$1,557,200.00View SEC Filing  
2/19/2015Martine A RothblattCEOSell9,662$155.99$1,507,175.38View SEC Filing  
2/19/2015Paul A MahonEVPSell6,000$155.72$934,320.00View SEC Filing  
2/17/2015David ZaccardelliCOOSell4,000$155.14$620,560.00View SEC Filing  
2/17/2015Martine A RothblattCEOSell2,592$152.28$394,709.76View SEC Filing  
2/12/2015Martine A RothblattCEOSell9,662$146.01$1,410,748.62View SEC Filing  
2/11/2015Martine A RothblattCEOSell2,211$147.29$325,658.19View SEC Filing  
2/10/2015David ZaccardelliCOOSell4,000$146.68$586,720.00View SEC Filing  
2/10/2015Roger JeffsCEOSell10,000$146.68$1,466,800.00View SEC Filing  
2/9/2015Martine A RothblattCEOSell2,592$143.32$371,485.44View SEC Filing  
2/5/2015John Maxim FerrariCFOSell10,000$141.92$1,419,200.00View SEC Filing  
2/5/2015Martine A RothblattCEOSell11,773$141.07$1,660,817.11View SEC Filing  
2/5/2015Paul A MahonEVPSell6,000$141.92$851,520.00View SEC Filing  
2/5/2015Raymond DwekDirectorSell3,000$140.41$421,230.00View SEC Filing  
2/3/2015David ZaccardelliCOOSell4,000$141.99$567,960.00View SEC Filing  
2/3/2015Roger JeffsCEOSell10,000$141.99$1,419,900.00View SEC Filing  
1/29/2015Martine A RothblattCEOSell9,662$143.29$1,384,467.98View SEC Filing  
1/28/2015Martine A RothblattCEOSell2,211$145.49$321,678.39View SEC Filing  
1/27/2015David ZaccardelliCOOSell4,000$147.19$588,760.00View SEC Filing  
1/27/2015Roger JeffsCEOSell10,000$147.19$1,471,900.00View SEC Filing  
1/26/2015Martine A RothblattCEOSell2,592$145.89$378,146.88View SEC Filing  
1/22/2015Martine A RothblattCEOSell11,873$146.76$1,742,481.48View SEC Filing  
1/20/2015David ZaccardelliCOOSell4,000$146.48$585,920.00View SEC Filing  
1/20/2015Martine A RothblattCEOSell2,592$145.06$375,995.52View SEC Filing  
1/15/2015John Maxim FerrariCFOSell22,500$137.84$3,101,400.00View SEC Filing  
1/15/2015Martine A RothblattCEOSell9,662$137.51$1,328,621.62View SEC Filing  
1/15/2015Paul A MahonEVPSell6,000$137.84$827,040.00View SEC Filing  
1/14/2015Martine A RothblattCEOSell2,211$135.18$298,882.98View SEC Filing  
1/13/2015David ZaccardelliCOOSell3,000$134.71$404,130.00View SEC Filing  
1/13/2015Roger JeffsCEOSell10,000$134.71$1,347,100.00View SEC Filing  
1/12/2015Martine A RothblattCEOSell2,592$132.00$342,144.00View SEC Filing  
1/8/2015Christopher PatuskyDirectorSell5,000$128.13$640,650.00View SEC Filing  
1/8/2015Martine A RothblattCEOSell9,662$128.31$1,239,731.22View SEC Filing  
1/7/2015Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
1/6/2015David ZaccardelliCOOSell3,000$124.93$374,790.00View SEC Filing  
1/6/2015Roger JeffsCEOSell7,500$124.93$936,975.00View SEC Filing  
1/5/2015Martine A RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
1/2/2015Christopher CauseyDirectorSell3,000$129.25$387,750.00View SEC Filing  
1/2/2015Martine A RothblattCEOSell9,662$126.53$1,222,532.86View SEC Filing  
1/2/2015Paul A MahonEVPSell6,000$127.73$766,380.00View SEC Filing  
12/31/2014Martine A RothblattCEOSell2,211$131.35$290,414.85View SEC Filing  
12/30/2014Roger JeffsCEOSell10,000$130.80$1,308,000.00View SEC Filing  
12/29/2014Martine A RothblattCEOSell2,592$131.75$341,496.00View SEC Filing  
12/26/2014Martine A RothblattCEOSell9,662$131.85$1,273,934.70View SEC Filing  
12/24/2014Martine A RothblattCEOSell2,211$130.35$288,203.85View SEC Filing  
12/23/2014Roger JeffsCOOSell10,000$127.82$1,278,200.00View SEC Filing  
12/22/2014Martine A RothblattCEOSell2,592$133.45$345,902.40View SEC Filing  
12/19/2014Christopher CauseyDirectorSell1,500$131.47$197,205.00View SEC Filing  
12/18/2014John Maxim FerrariCFOSell10,000$131.11$1,311,100.00View SEC Filing  
12/18/2014Martine A RothblattCEOSell9,662$129.06$1,246,977.72View SEC Filing  
12/18/2014Paul A MahonEVPSell10,750$130.03$1,397,822.50View SEC Filing  
12/17/2014Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
12/15/2014Martine A RothblattCEOSell2,592$129.75$336,312.00View SEC Filing  
12/11/2014Martine A RothblattCEOSell9,662$130.98$1,265,528.76View SEC Filing  
12/10/2014Martine A RothblattCEOSell2,211$132.77$293,554.47View SEC Filing  
12/9/2014Roger JeffsCOOSell10,000$134.80$1,348,000.00View SEC Filing  
12/8/2014Martine A RothblattCEOSell2,592$132.34$343,025.28View SEC Filing  
12/4/2014John Maxim FerrariCFOSell10,000$129.05$1,290,500.00View SEC Filing  
12/4/2014Martine A RothblattCEOSell11,873$131.32$1,559,162.36View SEC Filing  
12/4/2014Paul A MahonEVPSell11,000$129.92$1,429,120.00View SEC Filing  
12/4/2014Raymond DwekDirectorSell3,000$131.58$394,740.00View SEC Filing  
12/2/2014Roger JeffsCOOSell10,000$133.63$1,336,300.00View SEC Filing  
12/1/2014Martine A RothblattCEOSell2,592$132.92$344,528.64View SEC Filing  
11/28/2014Martine A RothblattCEOSell11,873$132.77$1,576,378.21View SEC Filing  
11/25/2014Roger JeffsCOOSell10,000$131.30$1,313,000.00View SEC Filing  
11/24/2014Martine A RothblattCEOSell2,592$130.72$338,826.24View SEC Filing  
11/21/2014Roger JeffsCOOSell10,000$130.15$1,301,500.00View SEC Filing  
11/20/2014Christopher CauseyDirectorSell1,500$127.20$190,800.00View SEC Filing  
11/20/2014John Maxim FerrariCFOSell10,000$129.22$1,292,200.00View SEC Filing  
11/20/2014Martine A RothblattCEOSell9,662$128.86$1,245,045.32View SEC Filing  
11/20/2014Paul A MahonEVPSell11,000$129.02$1,419,220.00View SEC Filing  
11/19/2014Martine A RothblattCEOSell2,211$128.69$284,533.59View SEC Filing  
11/18/2014Roger JeffsCOOSell10,000$128.21$1,282,100.00View SEC Filing  
11/17/2014Martine A RothblattCEOSell2,592$125.65$325,684.80View SEC Filing  
11/13/2014Martine A RothblattCEOSell9,662$124.79$1,205,720.98View SEC Filing  
11/12/2014Martine A RothblattCEOSell2,211$122.88$271,687.68View SEC Filing  
11/10/2014Martine A RothblattCEOSell2,592$125.14$324,362.88View SEC Filing  
11/7/2014Christopher PatuskyDirectorSell5,000$124.49$622,450.00View SEC Filing  
11/7/2014Roger JeffsCOOSell10,000$124.46$1,244,600.00View SEC Filing  
11/6/2014Christopher CauseyDirectorSell1,500$122.89$184,335.00View SEC Filing  
11/6/2014Martine A RothblattCEOSell4,115$125.33$515,732.95View SEC Filing  
11/6/2014Paul A MahonEVPSell5,000$125.02$625,100.00View SEC Filing  
11/5/2014Martine A RothblattCEOSell2,211$124.31$274,849.41View SEC Filing  
11/3/2014Martine A RothblattCEOSell2,592$127.49$330,454.08View SEC Filing  
10/30/2014Martine A RothblattCEOSell9,662$130.42$1,260,118.04View SEC Filing  
10/29/2014Martine A RothblattCEOSell2,211$131.10$289,862.10View SEC Filing  
10/27/2014Martine A RothblattCEOSell2,592$132.16$342,558.72View SEC Filing  
10/23/2014Martine A RothblattCEOSell11,873$129.97$1,543,133.81View SEC Filing  
10/23/2014Paul A MahonEVPSell11,000$127.04$1,397,440.00View SEC Filing  
10/13/2014Martine A RothblattCEOSell2,592$124.31$322,211.52View SEC Filing  
10/9/2014Martine A RothblattCEOSell9,662$129.97$1,255,770.14View SEC Filing  
10/9/2014Paul A MahonEVPSell5,000$130.59$652,950.00View SEC Filing  
10/8/2014Martine A RothblattCEOSell2,211$131.50$290,746.50View SEC Filing  
10/7/2014Roger JeffsCOOSell35,000$130.14$4,554,900.00View SEC Filing  
10/6/2014Martine A RothblattCEOSell2,592$129.32$335,197.44View SEC Filing  
10/3/2014Roger JeffsCOOSell10,000$129.79$1,297,900.00View SEC Filing  
10/2/2014Christopher CauseyDirectorSell1,500$130.65$195,975.00View SEC Filing  
10/2/2014John Maxim FerrariCFOSell10,000$129.46$1,294,600.00View SEC Filing  
10/2/2014Martine A RothblattCEOSell9,662$127.72$1,234,030.64View SEC Filing  
10/2/2014Paul A MahonEVPSell6,000$129.46$776,760.00View SEC Filing  
10/1/2014Martine A RothblattCEOSell2,211$127.40$281,681.40View SEC Filing  
9/30/2014Roger JeffsCOOSell20,000$128.65$2,573,000.00View SEC Filing  
9/25/2014Martine A RothblattCEOSell5,547$134.26$744,740.22View SEC Filing  
9/25/2014Paul A MahonEVPSell5,000$133.77$668,850.00View SEC Filing  
9/25/2014Richard GiltnerDirectorSell20,000$134.94$2,698,800.00View SEC Filing  
9/23/2014Roger JeffsCOOSell50,000$131.02$6,551,000.00View SEC Filing  
9/19/2014Roger JeffsCOOSell10,000$129.60$1,296,000.00View SEC Filing  
9/18/2014John Maxim FerrariCFOSell10,000$130.93$1,309,300.00View SEC Filing  
9/18/2014Martine A RothblattCEOSell9,662$127.35$1,230,455.70View SEC Filing  
9/18/2014Paul A MahonEVPSell6,000$130.93$785,580.00View SEC Filing  
9/17/2014Roger JeffsCOOSell20,000$127.01$2,540,200.00View SEC Filing  
9/15/2014Martine A RothblattCEOSell50,000$124.52$6,226,000.00View SEC Filing  
9/11/2014Martine A RothblattCEOSell9,662$120.79$1,167,072.98View SEC Filing  
9/11/2014Paul A MahonEVPSell5,000$120.70$603,500.00View SEC Filing  
9/10/2014Martine A RothblattCEOSell50,000$120.01$6,000,500.00View SEC Filing  
9/10/2014Richard GiltnerDirectorSell20,000$119.95$2,399,000.00View SEC Filing  
9/5/2014Roger JeffsCOOSell10,000$111.29$1,112,900.00View SEC Filing  
9/4/2014John Maxim FerrariCFOSell10,000$112.38$1,123,800.00View SEC Filing  
9/4/2014Martine A RothblattCEOSell9,662$112.87$1,090,549.94View SEC Filing  
9/4/2014Paul A MahonEVPSell6,000$112.38$674,280.00View SEC Filing  
9/4/2014Raymond DwekDirectorSell3,000$113.40$340,200.00View SEC Filing  
8/28/2014Martine A RothblattCEOSell7,014$92.46$648,514.44View SEC Filing  
8/28/2014Paul A MahonEVPSell5,000$92.07$460,350.00View SEC Filing  
8/21/2014John Maxim FerrariCFOSell10,000$93.75$937,500.00View SEC Filing  
8/21/2014Martine A RothblattCEOSell9,640$93.13$897,773.20View SEC Filing  
8/15/2014Christopher CauseyDirectorSell1,500$91.14$136,710.00View SEC Filing  
8/14/2014Martine A RothblattCEOSell4,115$88.39$363,724.85View SEC Filing  
8/14/2014Paul A MahonEVPSell10,000$88.41$884,100.00View SEC Filing  
8/7/2014Christopher PatuskyDirectorSell5,000$88.23$441,150.00View SEC Filing  
8/7/2014John Maxim FerrariCFOSell10,000$86.44$864,400.00View SEC Filing  
8/7/2014Martine A RothblattCEOSell4,115$88.40$363,766.00View SEC Filing  
8/1/2014Raymond DwekDirectorSell3,000$89.52$268,560.00View SEC Filing  
8/1/2014Roger JeffsCOOSell10,000$89.88$898,800.00View SEC Filing  
7/31/2014Martine A RothblattCEOSell3,933$90.95$357,706.35View SEC Filing  
7/29/2014Roger JeffsCOOSell50,000$96.25$4,812,500.00View SEC Filing  
7/25/2014Roger JeffsCOOSell10,000$91.54$915,400.00View SEC Filing  
7/24/2014Martine A RothblattCEOSell9,228$93.15$859,588.20View SEC Filing  
7/17/2014John Maxim FerrariCFOSell10,000$89.74$897,400.00View SEC Filing  
7/17/2014Martine A RothblattCEOSell3,833$90.87$348,304.71View SEC Filing  
7/11/2014Roger JeffsCOOSell10,000$93.06$930,600.00View SEC Filing  
7/10/2014Martine A RothblattCEOSell9,187$92.33$848,235.71View SEC Filing  
7/3/2014Christopher CauseyDirectorSell1,500$91.62$137,430.00View SEC Filing  
7/3/2014John Maxim FerrariCFOSell10,000$90.58$905,800.00View SEC Filing  
7/3/2014Martine A RothblattCEOSell3,833$91.37$350,221.21View SEC Filing  
6/26/2014Martine A RothblattCEOSell3,833$87.23$334,352.59View SEC Filing  
6/20/2014Roger JeffsCOOSell10,000$87.00$870,000.00View SEC Filing  
6/19/2014John Maxim FerrariCFOSell10,000$87.02$870,200.00View SEC Filing  
6/19/2014Martine A RothblattCEOSell3,833$85.68$328,411.44View SEC Filing  
6/19/2014Paul A MahonEVPSell2,000$85.67$171,340.00View SEC Filing  
6/12/2014Martine A RothblattCEOSell9,066$98.22$890,462.52View SEC Filing  
6/10/2014Roger JeffsCOOSell10,000$96.29$962,900.00View SEC Filing  
6/9/2014Roger JeffsCOOSell10,000$96.32$963,200.00View SEC Filing  
6/5/2014Christopher CauseyDirectorSell1,500$96.48$144,720.00View SEC Filing  
6/5/2014Martine A RothblattCEOSell9,066$96.46$874,506.36View SEC Filing  
6/5/2014Paul A MahonEVPSell6,000$96.50$579,000.00View SEC Filing  
6/3/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
5/29/2014Martine A RothblattCEOSell9,066$95.27$863,717.82View SEC Filing  
5/27/2014Roger JeffsCOOSell10,000$99.14$991,400.00View SEC Filing  
5/22/2014Louis SullivanDirectorSell30,000$101.46$3,043,800.00View SEC Filing  
5/22/2014Martine RothblattCEOSell9,066$101.35$918,839.10140View SEC Filing  
5/20/2014Roger JeffsCOOSell10,000$99.91$999,100.001,234View SEC Filing  
5/16/2014Roger JeffsCOOSell10,000$100.00$1,000,000.001,234View SEC Filing  
5/15/2014John Maxim FerrariCFOSell10,000$101.49$1,014,900.00407View SEC Filing  
5/15/2014Martine RothblattCEOSell9,066$100.88$914,578.08140View SEC Filing  
5/15/2014Paul MahonEVPSell6,000$100.86$605,160.0034,832View SEC Filing  
5/13/2014Roger JeffsCOOSell10,000$105.53$1,055,300.001,234View SEC Filing  
5/8/2014Christopher PatuskyDirectorSell5,000$107.17$535,850.00View SEC Filing  
5/8/2014Martine RothblattCEOSell9,066$107.83$977,586.78140View SEC Filing  
5/6/2014Roger JeffsCOOSell10,000$106.50$1,065,000.001,234View SEC Filing  
5/2/2014Roger JeffsCOOSell10,000$102.00$1,020,000.001,234View SEC Filing  
5/1/2014Christopher CauseyDirectorSell1,500$99.30$148,950.00733View SEC Filing  
5/1/2014John Maxim FerrariCFOSell10,000$102.20$1,022,000.00407View SEC Filing  
5/1/2014Martine RothblattCEOSell9,066$101.84$923,281.44140View SEC Filing  
5/1/2014Paul MahonEVPSell6,000$102.71$616,260.0034,832View SEC Filing  
4/29/2014Roger JeffsCOOSell10,000$95.00$950,000.001,234View SEC Filing  
4/24/2014Martine RothblattCEOSell9,066$92.45$838,151.70140View SEC Filing  
4/22/2014Roger JeffsCOOSell10,000$96.00$960,000.001,234View SEC Filing  
4/17/2014John Maxim FerrariCFOSell10,000$96.20$962,000.00407View SEC Filing  
4/17/2014Martine RothblattCEOSell9,066$98.48$892,819.68140View SEC Filing  
4/17/2014Paul MahonEVPSell6,000$98.37$590,220.0034,832View SEC Filing  
4/15/2014Roger JeffsCOOSell10,000$95.06$950,600.001,234View SEC Filing  
4/10/2014Martine RothblattCEOSell9,066$96.18$871,967.88140View SEC Filing  
4/8/2014Roger JeffsCOOSell10,000$95.00$950,000.001,234View SEC Filing  
4/4/2014Roger JeffsCOOSell10,000$93.22$932,200.001,234View SEC Filing  
4/3/2014Christopher CauseyDirectorSell1,500$95.67$143,505.00733View SEC Filing  
4/3/2014John Maxim FerrariCFOSell10,000$93.22$932,200.00407View SEC Filing  
4/3/2014Martine RothblattCEOSell9,066$93.74$849,846.84140View SEC Filing  
4/3/2014Paul MahonEVPSell6,000$93.10$558,600.0034,832View SEC Filing  
4/1/2014Roger JeffsCOOSell10,000$95.44$954,400.001,234View SEC Filing  
3/27/2014Martine RothblattCEOSell9,066$93.35$846,311.10140View SEC Filing  
3/25/2014Roger JeffsCOOSell10,000$95.64$956,400.001,234View SEC Filing  
3/21/2014Roger JeffsCOOSell10,000$93.84$938,400.001,234View SEC Filing  
3/20/2014Christopher CauseyDirectorSell1,500$96.04$144,060.00733View SEC Filing  
3/20/2014John Maxim FerrariCFOSell10,000$96.11$961,100.00407View SEC Filing  
3/20/2014Martine RothblattCEOSell9,065$96.76$877,129.40140View SEC Filing  
3/20/2014Paul MahonEVPSell6,000$96.81$580,860.0034,832View SEC Filing  
3/18/2014Roger JeffsCOOSell10,000$96.51$965,100.001,234View SEC Filing  
3/13/2014Martine RothblattCEOSell3,833$95.64$366,588.12140View SEC Filing  
3/7/2014Roger JeffsCOOSell10,000$99.02$990,200.001,234View SEC Filing  
3/6/2014Christopher PatuskyDirectorSell5,000$101.39$506,950.00View SEC Filing  
3/6/2014John Maxim FerrariCFOSell10,000$99.07$990,700.00407View SEC Filing  
3/6/2014Martine RothblattCEOSell3,833$102.77$393,917.41140View SEC Filing  
3/6/2014Paul MahonEVPSell6,000$101.93$611,580.0034,832View SEC Filing  
2/28/2014Ray KurzweilDirectorSell15,000$101.42$1,521,300.00View SEC Filing  
2/27/2014Martine RothblattCEOSell3,833$100.68$385,906.44140View SEC Filing  
2/21/2014Roger JeffsCOOSell10,000$104.89$1,048,900.00897View SEC Filing  
2/20/2014Martine RothblattCEOSell3,833$103.91$398,287.03140View SEC Filing  
2/20/2014Paul MahonEVPSell6,000$104.63$627,780.0034,490View SEC Filing  
2/13/2014Martine RothblattCEOSell3,833$99.87$382,801.71140View SEC Filing  
2/7/2014Roger JeffsCOOSell10,000$96.61$966,100.00897View SEC Filing  
2/6/2014Martine RothblattCEOSell3,833$97.26$372,797.58140View SEC Filing  
2/6/2014Paul MahonEVPSell6,000$97.41$584,460.0034,490View SEC Filing  
2/6/2014Raymond DwekDirectorSell3,000$97.33$291,990.00View SEC Filing  
1/30/2014Martine RothblattCEOSell3,833$106.25$407,256.25140View SEC Filing  
1/23/2014Martine RothblattCEOSell3,833$111.78$428,452.74140View SEC Filing  
1/17/2014Roger JeffsCOOSell10,000$113.03$1,130,300.00897View SEC Filing  
1/16/2014Martine RothblattCEOSell3,833$111.21$426,267.93140View SEC Filing  
1/16/2014Paul MahonEVPSell6,000$111.98$671,880.0034,490View SEC Filing  
1/9/2014Christopher PatuskyDirectorSell5,000$110.00$550,000.00View SEC Filing  
1/9/2014Martine RothblattCEOSell3,833$108.35$415,305.55140View SEC Filing  
1/3/2014Roger JeffsCOOSell10,000$110.72$1,107,200.00897View SEC Filing  
1/2/2014Martine RothblattCEOSell3,833$111.54$427,532.82140View SEC Filing  
1/2/2014Paul MahonEVPSell6,000$110.78$664,680.0034,490View SEC Filing  
1/2/2014Raymond DwekDirectorSell3,000$111.41$334,230.00View SEC Filing  
12/31/2013Martine RothblattCEOSell18,140$112.64$2,043,289.60140View SEC Filing  
12/30/2013Martine RothblattCEOSell18,147$111.60$2,025,205.20140View SEC Filing  
12/27/2013Martine RothblattCEOSell18,147$113.15$2,053,333.05140View SEC Filing  
12/26/2013Martine RothblattCEOSell21,981$111.95$2,460,772.95140View SEC Filing  
12/24/2013Martine RothblattCEOSell18,149$114.05$2,069,893.45140View SEC Filing  
12/23/2013Martine RothblattCEOSell5,743$109.71$630,064.53140View SEC Filing  
12/20/2013Martine RothblattCEOSell18,149$86.72$1,573,881.28140View SEC Filing  
12/20/2013Roger JeffsCOOSell8,250$87.84$724,680.00897View SEC Filing  
12/19/2013Martine RothblattCEOSell21,982$86.73$1,906,498.86140View SEC Filing  
12/19/2013Paul MahonEVPSell6,000$86.45$518,700.0034,490View SEC Filing  
12/18/2013Martine RothblattCEOSell18,149$86.36$1,567,347.64140View SEC Filing  
12/17/2013Martine RothblattCEOSell12,251$86.49$1,059,588.99140View SEC Filing  
12/6/2013Roger JeffsCOOSell10,000$90.97$909,700.0019,760View SEC Filing  
12/5/2013Martine RothblattCEOSell3,833$89.79$344,165.07140View SEC Filing  
12/5/2013Paul MahonEVPSell6,000$89.18$535,080.0034,490View SEC Filing  
12/5/2013Raymond DwekDirectorSell3,000$90.13$270,390.00View SEC Filing  
11/21/2013Martine RothblattCEOSell3,833$92.49$354,514.17140View SEC Filing  
11/21/2013Paul MahonEVPSell6,000$92.47$554,820.0034,490View SEC Filing  
11/15/2013Roger JeffsCOOSell10,000$94.00$940,000.0019,760View SEC Filing  
11/14/2013Christopher PatuskyDirectorSell5,500$91.65$504,075.00View SEC Filing  
11/14/2013Martine RothblattCEOSell3,833$91.60$351,102.80140View SEC Filing  
11/7/2013Christopher PatuskyDirectorSell3,500$90.51$316,785.00View SEC Filing  
11/7/2013Martine RothblattCEOSell3,833$89.47$342,938.51140View SEC Filing  
11/7/2013Paul MahonEVPSell6,000$89.60$537,600.0034,490View SEC Filing  
11/1/2013Raymond DwekDirectorSell3,000$89.18$267,540.00View SEC Filing  
11/1/2013Roger JeffsCOOSell10,000$90.34$903,400.00View SEC Filing  
10/31/2013Martine A RothblattCEOSell3,833$86.89$333,049.37View SEC Filing  
10/24/2013Martine A RothblattCEOSell3,833$83.77$321,090.41View SEC Filing  
10/18/2013Roger JeffsCOOSell10,000$82.47$824,700.00View SEC Filing  
10/17/2013John Maxim FerrariCFOSell2,750$82.01$225,527.50View SEC Filing  
10/17/2013Martine A RothblattCEOSell3,833$81.84$313,692.72View SEC Filing  
10/17/2013Paul A MahonEVPSell6,000$81.79$490,740.00View SEC Filing  
10/10/2013Martine RothblattCEOSell3,833$82.58$316,529.14140View SEC Filing  
10/4/2013Roger JeffsCOOSell10,000$85.48$854,800.00View SEC Filing  
10/3/2013Christopher CauseyDirectorSell1,500$83.15$124,725.00View SEC Filing  
10/3/2013John Maxim FerrariCFOSell4,500$84.67$381,015.00View SEC Filing  
10/3/2013Martine A RothblattCEOSell3,833$84.20$322,738.60View SEC Filing  
10/3/2013Paul A MahonEVPSell6,000$84.38$506,280.00View SEC Filing  
9/26/2013Martine RothblattCEOSell3,833$78.41$300,545.53140View SEC Filing  
9/20/2013Roger JeffsCOOSell10,000$77.86$778,600.0019,760View SEC Filing  
9/19/2013John Maxim FerrariCFOSell4,500$78.67$354,015.00407View SEC Filing  
9/19/2013Martine RothblattCEOSell3,833$78.12$299,433.96140View SEC Filing  
9/19/2013Paul MahonEVPSell6,000$78.02$468,120.0034,490View SEC Filing  
9/12/2013Martine A RothblattCEOSell3,833$76.98$295,064.34View SEC Filing  
9/6/2013Roger JeffsCOOSell10,000$73.67$736,700.00View SEC Filing  
9/5/2013Christopher CauseyDirectorSell1,500$73.11$109,665.00View SEC Filing  
9/5/2013John Maxim FerrariCFOSell4,500$74.17$333,765.00View SEC Filing  
9/5/2013Martine A RothblattCEOSell3,833$73.63$282,223.79View SEC Filing  
9/5/2013Paul A MahonEVPSell6,000$73.29$439,740.00View SEC Filing  
8/29/2013Martine RothblattCEOSell3,833$72.76$278,889.08140View SEC Filing  
8/22/2013Martine RothblattCEOSell3,833$72.06$276,205.98140View SEC Filing  
8/16/2013Roger JeffsCOOSell10,000$71.21$712,100.0019,760View SEC Filing  
8/15/2013John Maxim FerrariCFOSell4,500$71.14$320,130.00View SEC Filing  
8/15/2013Martine RothblattCEOSell3,833$71.58$274,366.14140View SEC Filing  
8/15/2013Paul MahonEVPSell6,000$71.34$428,040.0034,490View SEC Filing  
8/8/2013Martine RothblattCEOSell3,833$73.11$280,230.63140View SEC Filing  
8/2/2013Roger JeffsCOOSell10,000$76.69$766,900.00View SEC Filing  
8/1/2013John Maxim FerrariCFOSell4,500$75.87$341,415.00View SEC Filing  
8/1/2013Martine A RothblattCEOSell3,833$75.97$291,193.01View SEC Filing  
8/1/2013Paul A MahonEVPSell6,000$75.91$455,460.00View SEC Filing  
8/1/2013Raymond DwekDirectorSell3,000$75.94$227,820.00View SEC Filing  
7/31/2013R Paul GrayDirectorSell7,500$74.93$561,975.00View SEC Filing  
7/25/2013Martine A RothblattCEOSell3,833$71.45$273,867.85View SEC Filing  
7/19/2013Roger JeffsCOOSell10,000$70.00$700,000.00View SEC Filing  
7/18/2013John Maxim FerrariCFOSell9,000$69.85$628,650.00View SEC Filing  
7/18/2013Martine A RothblattCEOSell3,833$68.96$264,323.68View SEC Filing  
7/18/2013Paul A MahonEVPSell6,000$69.15$414,900.00View SEC Filing  
7/11/2013Martine A RothblattCEOSell3,837$67.94$260,685.78View SEC Filing  
7/5/2013Christopher CauseyDirectorSell1,500$66.33$99,495.00View SEC Filing  
7/5/2013Martine A RothblattCEOSell3,863$67.28$259,902.64View SEC Filing  
7/5/2013Paul A MahonEVPSell6,000$67.04$402,240.00View SEC Filing  
7/5/2013Roger JeffsCOOSell10,000$67.21$672,100.00View SEC Filing  
6/21/2013Roger JeffsCOOSell10,000$63.34$633,400.00View SEC Filing  
6/20/2013John Maxim FerrariCFOSell4,500$63.22$284,490.00View SEC Filing  
6/20/2013Paul A MahonEVPSell6,000$63.29$379,740.00View SEC Filing  
6/7/2013Roger JeffsCOOSell10,000$67.00$670,000.00View SEC Filing  
6/6/2013John Maxim FerrariCFOSell4,500$64.84$291,780.00View SEC Filing  
6/6/2013Paul A MahonEVPSell6,000$63.84$383,040.00View SEC Filing  
6/6/2013Raymond DwekDirectorSell3,000$63.77$191,310.00View SEC Filing  
5/17/2013Roger JeffsCOOSell10,000$69.17$691,700.00View SEC Filing  
5/16/2013John Maxim FerrariCFOSell4,500$68.48$308,160.00View SEC Filing  
5/16/2013Paul A MahonEVPSell6,000$68.05$408,300.00View SEC Filing  
5/2/2013Paul A MahonEVPSell6,000$67.15$402,900.00View SEC Filing  
5/2/2013Raymond DwekDirectorSell3,000$66.75$200,250.00View SEC Filing  
4/11/2013Raymond DwekDirectorSell9,000$61.35$552,150.00View SEC Filing  
1/17/2013Paul A MahonEVPSell5,749$52.20$300,097.80View SEC Filing  
12/28/2012Martine A RothblattCEOBuy4,167$52.40$218,350.80View SEC Filing  
12/26/2012Martine A RothblattCEOBuy6,000$52.40$314,400.00View SEC Filing  
12/21/2012Martine A RothblattCEOBuy9,000$51.85$466,650.00View SEC Filing  
11/26/2012Christopher CauseyDirectorSell1,500$53.33$79,995.00View SEC Filing  
10/4/2012Christopher CauseyDirectorSell1,500$58.33$87,495.00View SEC Filing  
10/4/2012John Maxim FerrariCFOSell1,550$58.00$89,900.00View SEC Filing  
10/4/2012Paul A MahonEVPSell6,000$38.00$228,000.00View SEC Filing  
9/6/2012Christopher CauseyDirectorSell1,500$55.94$83,910.00View SEC Filing  
9/5/2012Christopher PatuskyDirectorSell2,000$55.47$110,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

United Therapeutics (NASDAQ UTHR) News Headlines

Source:
DateHeadline
Zacks: Brokerages Anticipate United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 MillionZacks: Brokerages Anticipate United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 Million
www.americanbankingnews.com - February 19 at 9:08 AM
Valideas Top Five Healthcare Stocks Based On Benjamin Graham - 2/18/2018 - NasdaqValidea's Top Five Healthcare Stocks Based On Benjamin Graham - 2/18/2018 - Nasdaq
www.nasdaq.com - February 19 at 8:02 AM
PCRX Slumps On FDA Panel Feedback, DOVA Hits Record High ... - NasdaqPCRX Slumps On FDA Panel Feedback, DOVA Hits Record High ... - Nasdaq
www.nasdaq.com - February 16 at 8:04 AM
United Therapeutics Corporation To Report Fourth Quarter And Annual 2017 Financial Results Before The Market ... - PR Newswire (press release)United Therapeutics Corporation To Report Fourth Quarter And Annual 2017 Financial Results Before The Market ... - PR Newswire (press release)
www.prnewswire.com - February 14 at 8:00 AM
United Therapeutics Corporation To Report Fourth Quarter And Annual 2017 Financial Results Before The Market Opens On Wednesday, February 21, 2018United Therapeutics Corporation To Report Fourth Quarter And Annual 2017 Financial Results Before The Market Opens On Wednesday, February 21, 2018
finance.yahoo.com - February 14 at 8:00 AM
United Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by BrokeragesUnited Therapeutics Co. (UTHR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 13 at 5:20 PM
Axovant Shares Crater as CEO and President Both Resign - TheStreet - TheStreet.comAxovant Shares Crater as CEO and President Both Resign - TheStreet - TheStreet.com
www.thestreet.com - February 13 at 8:00 AM
United Therapeutics (UTHR) Set to Announce Quarterly Earnings on TuesdayUnited Therapeutics (UTHR) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 3:32 AM
United Therapeutics (UTHR) Downgraded by ValuEngineUnited Therapeutics (UTHR) Downgraded by ValuEngine
www.americanbankingnews.com - February 4 at 9:02 AM
$415.79 Million in Sales Expected for United Therapeutics Co. (UTHR) This Quarter$415.79 Million in Sales Expected for United Therapeutics Co. (UTHR) This Quarter
www.americanbankingnews.com - February 2 at 2:22 PM
United Therapeutics Could See Tyvaso Pressure As MannKind Submits IND For Inhaled Version Of Treprostinil - Seeking AlphaUnited Therapeutics Could See Tyvaso Pressure As MannKind Submits IND For Inhaled Version Of Treprostinil - Seeking Alpha
seekingalpha.com - February 1 at 3:32 PM
A Deeper Look At MannKinds Journey On New Drug For Treatment Of PAH - Is It Viable? - Seeking AlphaA Deeper Look At MannKind's Journey On New Drug For Treatment Of PAH - Is It Viable? - Seeking Alpha
seekingalpha.com - January 31 at 7:58 AM
United Therapeutics (UTHR) Receives "Underperform" Rating from Credit Suisse GroupUnited Therapeutics (UTHR) Receives "Underperform" Rating from Credit Suisse Group
www.americanbankingnews.com - January 21 at 5:34 PM
United Therapeutics Co. (UTHR) Receives Average Rating of "Hold" from AnalystsUnited Therapeutics Co. (UTHR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 7:36 PM
UTHR Crosses Above Average Analyst TargetUTHR Crosses Above Average Analyst Target
www.nasdaq.com - January 18 at 11:43 AM
Faruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its ShareholdersFaruqi & Faruqi, LLP is Investigating United Therapeutics Corporation (UTHR) on Behalf of its Shareholders
finance.yahoo.com - January 17 at 4:23 PM
United Therapeutics (UTHR) Downgraded to "Sell" at BidaskClubUnited Therapeutics (UTHR) Downgraded to "Sell" at BidaskClub
www.americanbankingnews.com - January 17 at 12:14 AM
 Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 Million Analysts Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.79 Million
www.americanbankingnews.com - January 16 at 8:28 PM
United Therapeutics (UTHR) Rating Increased to Buy at Zacks Investment ResearchUnited Therapeutics (UTHR) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 8:52 AM
Oppenheimer Raises United Therapeutics (UTHR) Price Target to $180.00Oppenheimer Raises United Therapeutics (UTHR) Price Target to $180.00
www.americanbankingnews.com - January 5 at 6:28 PM
6 Companies Boosting Revenue and Earnings6 Companies Boosting Revenue and Earnings
finance.yahoo.com - January 5 at 3:58 PM
United Therapeutics (UTHR) Collaborates With Corsair Pharma - NasdaqUnited Therapeutics (UTHR) Collaborates With Corsair Pharma - Nasdaq
www.nasdaq.com - January 4 at 4:23 PM
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs - PR Newswire (press release)Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs - PR Newswire (press release)
www.prnewswire.com - January 4 at 4:23 PM
United Therapeutics (UTHR) Collaborates With Corsair PharmaUnited Therapeutics (UTHR) Collaborates With Corsair Pharma
finance.yahoo.com - January 4 at 4:23 PM
Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil ProdrugsCorsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
finance.yahoo.com - January 3 at 9:50 AM
Best Biotech Stock Trades and Mergers to Watch in 2018 - TheStreet.comBest Biotech Stock Trades and Mergers to Watch in 2018 - TheStreet.com
www.thestreet.com - January 2 at 5:03 PM
Q2 2018 Earnings Forecast for United Therapeutics Co. Issued By Wedbush (UTHR)Q2 2018 Earnings Forecast for United Therapeutics Co. Issued By Wedbush (UTHR)
www.americanbankingnews.com - January 1 at 3:56 AM
United Therapeutics (UTHR) Upgraded to Buy by ValuEngineUnited Therapeutics (UTHR) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - December 30 at 11:16 PM
 Brokerages Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.80 Million Brokerages Expect United Therapeutics Co. (UTHR) Will Post Quarterly Sales of $415.80 Million
www.americanbankingnews.com - December 30 at 9:38 AM
United Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare ConferenceUnited Therapeutics Corporation To Present At 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - December 28 at 10:18 AM
United Therapeutics Co. (UTHR) Expected to Post Earnings of $3.52 Per ShareUnited Therapeutics Co. (UTHR) Expected to Post Earnings of $3.52 Per Share
www.americanbankingnews.com - December 28 at 9:29 AM
United Therapeutics (UTHR) Outperform Rating Reaffirmed at WedbushUnited Therapeutics' (UTHR) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - December 27 at 8:48 AM
United Therapeutics (UTHR) Rating Increased to Strong-Buy at ValuEngineUnited Therapeutics (UTHR) Rating Increased to Strong-Buy at ValuEngine
www.americanbankingnews.com - December 27 at 12:16 AM
United Therapeutics Co. (UTHR) Given Average Recommendation of "Hold" by BrokeragesUnited Therapeutics Co. (UTHR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 5:57 PM
United Therapeutics settles federal anti-kickbacks case for $210MUnited Therapeutics settles federal anti-kickbacks case for $210M
www.bizjournals.com - December 21 at 4:24 PM
United Therapeutics to pay $210 million to settle government allegations of kickback paymentsUnited Therapeutics to pay $210 million to settle government allegations of kickback payments
finance.yahoo.com - December 20 at 4:20 PM
United Therapeutics to pay $210 mln to resolve U.S. kickback probeUnited Therapeutics to pay $210 mln to resolve U.S. kickback probe
finance.yahoo.com - December 20 at 4:20 PM
United Therapeutics (UTHR) Raised to "B" at TheStreetUnited Therapeutics (UTHR) Raised to "B" at TheStreet
www.americanbankingnews.com - December 19 at 11:02 PM
United Therapeutics Gets a Quantitative UpgradeUnited Therapeutics Gets a Quantitative Upgrade
finance.yahoo.com - December 18 at 4:19 PM
United Therapeutics Co. (UTHR) Expected to Post Quarterly Sales of $415.80 MillionUnited Therapeutics Co. (UTHR) Expected to Post Quarterly Sales of $415.80 Million
www.americanbankingnews.com - December 13 at 12:56 PM
United Therapeutics (UTHR) Rating Increased to Hold at BidaskClubUnited Therapeutics (UTHR) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - December 10 at 10:40 AM
United Therapeutics Corporation (UTHR) Director Christopher Causey Sells 580 SharesUnited Therapeutics Corporation (UTHR) Director Christopher Causey Sells 580 Shares
www.americanbankingnews.com - December 7 at 6:22 PM
How Did United Therapeutics’ Tyvaso and Orenitram Perform in 3Q17?How Did United Therapeutics’ Tyvaso and Orenitram Perform in 3Q17?
finance.yahoo.com - December 4 at 10:38 AM
United Therapeutics Corporation (UTHR) CEO Sells $160,026.95 in StockUnited Therapeutics Corporation (UTHR) CEO Sells $160,026.95 in Stock
www.americanbankingnews.com - December 1 at 10:26 PM
How United Therapeutics Performed in 3Q17How United Therapeutics Performed in 3Q17
finance.yahoo.com - December 1 at 5:52 PM
United Therapeutics Corporation (UTHR) Receives Average Recommendation of "Hold" from AnalystsUnited Therapeutics Corporation (UTHR) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - November 30 at 7:48 PM
United Therapeutics (UTHR) Shares Cross Above 200 DMAUnited Therapeutics (UTHR) Shares Cross Above 200 DMA
www.nasdaq.com - November 30 at 11:15 AM
United Therapeutics Corp. – Value Analysis (NASDAQ:UTHR) : November 29, 2017United Therapeutics Corp. – Value Analysis (NASDAQ:UTHR) : November 29, 2017
finance.yahoo.com - November 29 at 4:21 PM
United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,253 SharesUnited Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,253 Shares
www.americanbankingnews.com - November 28 at 1:58 PM
Zacks: Analysts Anticipate United Therapeutics Corporation (UTHR) Will Post Quarterly Sales of $406.47 MillionZacks: Analysts Anticipate United Therapeutics Corporation (UTHR) Will Post Quarterly Sales of $406.47 Million
www.americanbankingnews.com - November 25 at 8:36 AM

SEC Filings

United Therapeutics (NASDAQ:UTHR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

United Therapeutics (NASDAQ:UTHR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

United Therapeutics (NASDAQ UTHR) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.